BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jul 3, 2020
Translation in Brief

Tesla developing RNA therapeutic ‘microfactories’ for CureVac, plus CRISPR-directed RNA epigenetic modifications and Nucleix

...markets Bladder EpiCheck in the EU, where it has CE Mark approval. Targets Cas13b - CRISPR-associated protein 13b...
...like 3 METTL14 - Methyltransferase like 14 BioCentury Staff Bladder EpiCheck CureVac AG Broad Institute of MIT and Harvard Nucleix Ltd. CRISPR-associated protein 13b...
BioCentury | May 23, 2020
Translation in Brief

A three-compound dengue treatment; plus reversing antibiotic resistance, AbCellera-Lilly, reducing cholesterol with CRISPR and COVID cash for Sherlock

Hindering dengue by combining host- and virus-targeted drugs In a Cell Chemical Biology article , Stanford University scientists combined two host-targeted compounds with a virus-targeted compound to yield potent dengue treatment. A DHODH inhibitor tool compound,...
BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

Small molecule CD73 inhibitor for cancer A small molecule CD73 inhibitor from ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) has shown significant antitumor activity in vivo . ORIC-533 is slated for an IND submission in 1H21. CD73, which is...
BioCentury | Mar 28, 2020
Product Development

COVID-19 crisis spurs innovation in rapid diagnostic technologies

Companies across the world are mobilizing to answer the call for diagnostic innovation brought on by the COVID-19 crisis. The advances made during this time could change the course of this and future outbreaks, but...
BioCentury | Mar 20, 2020
Tools & Techniques

COVID-19 crisis brings CRISPR-Cas13 research into the spotlight

It makes sense that CRISPR-Cas13 would enter the limelight during the COVID-19 crisis, given that the SARS-CoV-2 is an RNA virus, and this Cas enzyme targets RNA. With diagnostics one of the most critical components...
BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Feb 19, 2020
Product Development

COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more

With support from HHS, Sanofi is adapting the platform behind its approved flu vaccine to develop a COVID-19 vaccine. A Sanofi (Euronext:SAN; NASDAQ:SNY) spokesperson told BioCentury the company will, at its own expense, develop a...
BioCentury | Oct 10, 2019
Tools & Techniques

Broad takes RNA CRISPR into viral infections

...protein 13 Lauren Martz, Associate Editor Broad Institute of MIT and Harvard Sherlock Biosciences Inc. CRISPR-associated protein 13a (Cas13a) (C2c2) CRISPR-associated protein 13b...
BioCentury | Oct 7, 2019
Emerging Company Profile

Gene editing vets launch Korro to convert RNA bases

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA...
Items per page:
1 - 10 of 30